Objective: The aim of the study was to determine the association between adjuvant chemotherapy for breast cancer and menopausal symptoms, sexual function, and quality of life.
T he majority of breast cancer patients are treated with adjuvant systemic therapy, often including chemotherapy. Chemotherapy aims to reduce the risk of recurrence and new cancers, but may also lead to short-and long-term adverse effects that impair physical and emotional health. 1, 2 In younger women, chemotherapy for breast cancer commonly causes amenorrhea and may induce menopause. 3 Vasomotor symptoms (hot flashes and night sweats) are highly prevalent and troublesome in breast cancer patients, [4] [5] [6] [7] but the relative impact of adjuvant chemotherapy on these symptoms is not well understood. Relative to healthy women, breast cancer patients treated with chemotherapy have worse vasomotor and sexual symptoms, [8] [9] [10] but it is not clear whether this phenomenon is attributable to chemotherapy, to other breast cancer treatments, or to cancer itself. Longitudinal 11, 12 and cross-sectional 13 studies comparing treatment modalities have had mixed findings, possibly because of inadequate control for current endocrine therapy, which is known to induce menopausal symptoms including vasomotor and vulvovaginal symptoms. 13, 14 Cross-sectional studies and clinical trials with younger, premenopausal women have implicated chemotherapy in deteriorating vasomotor 6 and sexual symptoms, 6, 15, 16 particularly vaginal dryness and dyspareunia. It is, however, not clear how much chemotherapy for breast cancer contributes to subsequent menopausal and sexual symptoms.
Early studies suggested that chemotherapy has short-term adverse effects on health-related quality of life that decreases 12 months after completion, [17] [18] [19] [20] with no effect among longterm survivors. 21 As chemotherapy regimens change and the population of breast cancer survivors grows, more information is needed about the associations between current regimens and vasomotor symptoms, sexual function, and quality of life to inform treatment decision-making. 22 The aim of this study was to compare these symptoms using validated instruments in a large clinic-based population of breast cancer survivors treated with adjuvant chemotherapy with breast cancer survivors who had not received chemotherapy, controlled for current age, time since menopause, and current endocrine therapy.
METHODS

Study population
The menopause clinic at King Edward Memorial Hospital, Western Australia, provides a multidisciplinary service for women with a breast cancer history 23 and serves a population of around 1.3 million. All women attending the clinic between 2003 and 2010 were invited to participate. The study was approved by the institutional ethics committee, and informed consent was obtained at the time of recruitment.
Measurement of participant characteristics
Detailed methods of data collection have been reported previously. 24 Gynecologic history and history of previous treatment for menopausal symptoms were recorded at the first visit. Current menopause status and menopause status before chemotherapy and after breast cancer treatment were collected at interview and, where possible, classified according to current Stages of Reproductive Aging Workshop criteria. 25 Information about stage and grade of breast cancer, estrogen and progesterone receptor status, and cancer treatment was obtained from the medical records. Chemotherapyinduced menopause was defined at interview, from the clinical history, as a woman who had described regular menstrual periods, and no vasomotor symptoms before and after chemotherapy had been amenorrheic for at least 12 months. For those who were hysterectomized, this was defined as new onset vasomotor symptoms after chemotherapy. Surgical date was used as a proxy for date of breast cancer diagnosis to calculate age at diagnosis. All participants who had ever undergone adjuvant chemotherapy had finished a minimum of 6 months before recruitment. As a secondary analysis, women currently using tamoxifen (with or without the gonadotropin-releasing-hormone agonist goserelin) were compared with those currently using any aromatase inhibitor (AI; anastrozole, letrozole, or exemestane).
Outcomes
Vasomotor symptoms
Participants were asked to report the number of hot flashes according to severity (''mild,'' ''moderate,'' ''severe,'' ''very severe'') over the previous 24 hours. For severity analyses, those reporting ''severe'' or ''very severe'' were compared with those who reported ''mild'' or ''moderate'' flashes, and those reporting 10 or more flashes per day (summed across severity) were compared with those with less than 10 flashes.
Current menopausal symptoms were collected using the Greene Climacteric Scale (GCS), 26 an extensively used and validated self-report questionnaire which measures how much women are currently troubled (''not at all,'' ''a little,'' ''quite a bit,'' ''extremely'') by 21 menopausal symptoms. For each individual symptom, we created binary severity variables comparing those who reported they were troubled by the symptom ''quite a bit'' or ''extremely'' to those who were troubled ''not at all'' or ''a little.'' The vasomotor domain comprises the two items: ''hot flashes'' and ''night sweats''; for the domain, we compared women who were troubled ''quite a bit'' or ''extremely'' by one or more of the two symptoms to those who were not.
Past-week vasomotor symptoms were evaluated using the Functional Assessment of Cancer Therapy (FACT) family of instruments 27 (www.facit.org), in particular hot flash, night sweats, and cold sweats items from the Endocrine Symptom Subscale (ESS). For each symptom, we created binary severity variables comparing those who reported having the symptom ''quite a bit'' or ''very much'' to those who had it ''somewhat,'' ''a little bit,'' or ''not at all.''
Gynecologic and sexual symptoms
Current gynecologic and sexual symptoms were collected using the GCS item ''loss of interest in sex'' and an identically administered item regarding ''vaginal dryness.'' Binary severity variables regarding individual symptoms were as above (''quite a bit'' or ''extremely'' vs ''not at all'' or ''a little''). Individual last-week sexual symptoms were collected using the ESS, and binary severity variables for individual symptoms created as above.
Sexual function during the previous month was reported using Fallowfield's Sexual Activity Questionnaire (SAQ). 28 The first section of the instrument, which investigates current sexual activity status, was completed by all participants. Section II was completed only by sexually inactive women to identify reasons for lack of sexual activity. Section III was completed only by sexually active women and consisted of 10 Likert-type items regarding sexual feelings and experiences in the previous months, in scales of Pleasure (SAQ-P), Discomfort (SAQ-D), and Habit (SAQ-H). 28 Women who had reported ''a little'' or ''not at all'' for three or more of the six items on the SAQ-P scale were classified as having low sexual pleasure. Those who endorsed ''very much'' for either of the two items of the SAQ-D (feeling pain or discomfort during penetration or noticing dryness of the vagina) were classified as having high sexual discomfort. The SAQ-H is a single item asking how that month's sexual frequency compares with what is usual for the respondent; those reporting ''less than usual'' were classified as having less frequent sexual activity.
CHEMOTHERAPY AND MENOPAUSAL SYMPTOMS
Psychological and other symptoms
Selected mood, sleep, and fatigue symptoms were classed together as ''psychological and other symptoms.'' The GCS 26 assesses current symptoms in a psychological domain comprising a 6-item anxiety and a 5-item depression subdomain, and further measures individual sleep and fatigue symptoms. Binary severity indicators were constructed for the domain and subdomain to identify women who had experienced being troubled ''quite a bit'' or ''extremely'' for over half the symptoms in each domain or subdomain. Binary severity variables indicating individual symptoms reported as ''quite a bit'' or ''extremely'' versus ''not at all'' or ''a little.'' Pastweek symptoms were collected using the ESS 29 and the Functional Assessment of Cancer Therapy-General (FACT-G) Scale, 27 with binary severity indicators created for symptoms as above.
Well-being and health-related quality of life Participants completed modules of the FACT instruments including the FACT-G, 27 the ESS, 29 and the Breast Cancer Subscale (version 4) (BCS). 30 The FACT-G provides global quality of life scores including physical well-being, social/ family well-being, and functional well-being (all 7-item scores). 31 The 19-item ESS 29 measures health-related quality of life specific to symptoms arising from antiestrogen endocrine therapy. The 9-item BCS measures breast cancer-related quality of life. In the FACT system, higher scores describe better function.
Statistical analyses
Continuous outcomes were summarized using medians and interquartile ranges (IQRs), except for well-being measures derived from the FACT instruments, which were summarized using means and standard deviations. By chemotherapy status (never/ever), distributions of binary variables were compared using Fisher's exact tests, categorical variables using x 2 tests, and continuous variables using the Mann-Whitney U test. Associations were summarized using crude and adjusted odds ratios (OR, aOR) and their 95% CIs, with the exception of FACT measures, for which associations were summarized using crude and adjusted average differences in mean values and their 95% CIs. The association of chemotherapy with severe menopausal symptoms (as described above) was analyzed using logistic regression models adjusted for current age, time since menopause, or in the case of premenopausal or indeterminate status women, time since symptoms (<1 y, 1 to <2 y, 2 to <5 y, 5 to <10 y, !10 y), and current use of any endocrine therapy (tamoxifen, goserelin, anastrozole, letrozole, or exemestane). Other covariates of interest included age at menopause and cause of menopause (natural menopause vs surgery, chemotherapy, or radiation; women with premenopausal or indeterminate menopausal status at clinic visit were grouped with the latter), but because these variables are highly correlated with current age and time since menopause, modeling them simultaneously resulted in substantial multicollinearity, producing less precise estimates in models with greater missing data (see Table 1 , Supplemental Digital Content 1, http://links.lww.com/MENO/A167). Current age and time since menopause were chosen as the principal covariates for adjustment to maximize data completeness and probable accuracy.
Current use of tamoxifen (with or without the gonadotropin-releasing-hormone agonist goserelin) was compared with current use of any AI (anastrozole, letrozole, or exemestane) using logistic regression models adjusted for time since menopause, current age, and chemotherapy status. As with analyses of chemotherapy, alternative models including time since menopause and cause of menopausal symptoms (see Table 2 , Supplemental Digital Content 2, http://links. lww.com/MENO/A168) were less stable and less precise than the more parsimonious model presented.
To address the potential impact of chemotherapy-induced menopause on our outcomes, we also compared vasomotor, sexual, and psychological symptoms and quality of life in those defined as having ''chemotherapy-induced menopause'' compared with other breast cancer survivors. Models were adjusted for current age, time since menopause, and current use of endocrine therapy.
For well-being scores derived from the FACT instruments, average mean differences between groups were calculated using linear regression models adjusted for the same variables as the corresponding logistic regression models. To compare measures of well-being to published scores for breast cancer patients, we estimated effect sizes with standardized mean differences calculated using Hedges' g. 32 As the published FACT ESS score was based on an older version of the instrument with one less item than the current version, we recalculated this score according to the instrument publisher's instructions.
Data analysis was conducted using Stata v.13.1 (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP), except for standardized mean differences, which were estimated using an online effect size calculator. 33 All hypothesis tests were two-sided, and P values<0.05 were considered statistically significant.
RESULTS
From 2003 to 2010, 824 symptomatic breast cancer survivors, all experiencing menopausal symptoms, were referred to the menopause and cancer service (see Fig. 1 ). The proportion of participants who completed enough items that the instrument could be validly scored was 91% (n ¼ 729) for the GCS, 47% (n ¼ 376) for the SAQ, and 49% (n ¼ 393) for any section of the FACT instruments. Instrument completion did not differ significantly by chemotherapy treatment or AI use status, and completers and noncompleters did not differ significantly in current age, time since menopause, or menopause status before diagnosis (data not shown).
Of the 803 breast cancer survivors for whom systemic treatment information was available (Table 1) , 465 (58%) had received adjuvant chemotherapy and 338 (42%) had not. Of women ever treated with chemotherapy, 263 (56.6%) met MARINO ET AL the criteria for chemotherapy-induced menopause. Women treated with adjuvant chemotherapy were significantly younger (median age 48 y, range from 28 to 74 y) compared with those who had not had chemotherapy (median age 56 y, range from 35 to 82 y, P < 0.001) ( Table 1) . Half of participants (400/803) were currently using antiestrogen endocrine therapy, including 247 (53%) who had also received chemotherapy (Table 1) . Very few women were currently taking estrogen-containing hormone therapy (never chemotherapy n ¼ 10, 3.0% vs ever chemotherapy n ¼ 11, 2.4%, P ¼ 0.7) ( Table 1) .
Of those using antiestrogen endocrine therapy, 239 (59.8%) used tamoxifen only, 93 (23.3%) anastrozole only, 42 (10.5%) letrozole only, and 6 (1.5%) each goserelin and exemestane only. Fourteen women took goserelin with another agent: 11 (2.8%) tamoxifen, 1 (0.2%) letrozole, and 2 (0.5%) anastrozole. Six (1.5%) were known to be taking antiestrogen endocrine therapy, but information about type was missing.
As expected, the 145 AI users were significantly older (median age 54 y, IQR 50-61 y, range 31-74 y) than the 256 tamoxifen users (median age 48 y, IQR 45-53 y, range 30-75 y, P < 0.001).
Vasomotor symptoms
After adjusting for current age, time since menopause, and current use of endocrine therapy, there was no difference in the likelihood, number, or severity of vasomotor symptoms between those who had received chemotherapy compared with those who had not (Table 2 ). These findings did not differ in alternative models further adjusted for age at menopause and cause of menopause (natural menopause vs surgery, chemotherapy, or radiation, counting premenopausal women and those with indeterminate menopause status among the latter) (see Table 1 Table 2 , Supplemental Digital Content 2, http://links.lww.com/MENO/A168).
Women with chemotherapy-induced menopause did not differ from those with other causes of menopause in vasomotor symptoms (data not shown).
Gynecologic and sexual symptoms
Severe and troublesome vaginal dryness and loss of interest in sex were both common, but after adjusting for current endocrine therapy use, current age, and time since menopause, there were no significant differences associated with previous chemotherapy (Table 3 ). In those who were sexually active (never chemotherapy n ¼ 93, 56.4%; ever chemotherapy n ¼ 131, 62.1%, P ¼ 0.3), those who had received chemotherapy were more likely to report ''severe pain'' with intercourse than those who had not (31.6% vs 20.0%, P ¼ 0.02) ( Table 3) . After adjusting for current endocrine therapy use, current age, and time since menopause, there were no significant differences in global past-month measures of sexual pleasure, discomfort, or habit as measured by the SAQ (Table 3) . These findings did not differ in alternative models further adjusted for time since menopause and cause of menopausal symptoms (see Table 1 , Supplemental Digital Content 1, http://links.lww.com/MENO/A167).
Compared with tamoxifen users, AI users were more likely to report severe current trouble with vaginal dryness (58.1% vs 38.2%, aOR 2.03, 95% CI 1.25-3.32, P ¼ 0.005), past-week vaginal dryness (41.5% vs 23.6%, aOR 2.46, 95% CI 1.21-5.02, P ¼ 0.01), and past-week pain or discomfort with intercourse (37.7% vs 16.8%, aOR 3.08, 95% CI 1.34-7.09, P ¼ 0.008). These findings did not substantively differ in more extensively adjusted analysis (see Table 2 , Supplemental Digital Content 2, http://links.lww.com/MENO/A168).
Women with chemotherapy-induced menopause were more likely to have had severe pain/discomfort with intercourse than those with other causes of menopause, but otherwise did not differ in gynecologic or sexual symptoms (data not shown).
Neuropsychological symptoms
Sleep disturbance in the previous week was significantly less common in those treated with chemotherapy (Table 4) . These findings did not differ in alternative models further adjusted for time since menopause and cause of menopausal symptoms (see Table 1 , Supplemental Digital Content 1, http://links.lww.com/MENO/A167).
AI users did not differ from tamoxifen users in neuropsychological symptoms. Women with chemotherapyinduced menopause did not differ from those with other causes of menopause in neuropsychological symptoms (data not shown).
Well-being and health-related quality of life
Those treated with chemotherapy had worse physical well-being and breast cancer-specific quality of life CHEMOTHERAPY AND MENOPAUSAL SYMPTOMS (Table 5 ; physical well-being: P ¼ 0.03, BCS: P ¼ 0.02). There were no significant differences between those who did and did not receive chemotherapy in functional wellbeing, social/family well-being, or endocrine symptomspecific quality of life (Table 5 ; P N.S. for all). Participants' FACT subscale scores were generally worse than published breast cancer norms, 27 with the largest negative effect on health-related quality of life related to antiestrogenic endocrine treatment, particularly among women who had ever been treated with chemotherapy.
Women with chemotherapy-induced menopause did not differ in quality of life from those with other causes of menopause (data not shown).
DISCUSSION
We compared differences in vasomotor symptoms, sexual and psychological symptoms, and quality of life in a large and diverse population of breast cancer survivors treated with adjuvant chemotherapy with those who had not received chemotherapy. This is the first study to provide this broad spectrum of outcomes in a population unrestricted by age or menopause status and large enough to account for age and antiestrogen endocrine therapy, which is known to cause menopausal symptoms.
Although there is no doubt that women who permanently cease ovulating after chemotherapy experience at least shortterm vasomotor symptoms, 6, 12, 13, 34 our study adds to a small body of reports 11, 35, 36 suggesting that chemotherapy does not result in more severe hot flashes or night sweats compared with other cancer therapy in the population of breast cancer survivors as a whole.
Although vasomotor symptoms did not differ according to chemotherapy use, we did find that chemotherapy was associated with severe pain with vaginal intercourse but not to other measures of sexual dysfunction. Sexual difficulties are common in cancer survivors and are a priority for breast cancer survivors of all ages. [37] [38] [39] Reduced sexual function may compromise quality of life. 40 Younger breast cancer survivors have been shown to have global sexual function problems, 15, 16, 38, 41, 42 driven by dyspareunia, vaginal dryness, and body image issues, 43, 44 with mixed evidence regarding recovery over the longer term. 11, 15, 21 In the few studies that included older women, the evidence has been more mixed 11, 43, 46 ). Because women may be reluctant to raise problems with sexual function, the apparent prevalence of severe sexual symptoms suggests that clinicians should specifically address this in management. Recent evidence suggests that vulvar rather than vaginal symptoms may contribute to discomfort during sexual activity in breast cancer survivors. 47 Our finding that vaginal dryness did not differ by chemotherapy history despite greater pain during sexual intercourse might support this hypothesis, but requires further investigation.
Consistent with previous data, 45, 48, 49 we observed that current severe vaginal dryness and recent pain with intercourse were more common in AI users compared with tamoxifen users, adjusted for current age, and time since menopause. Level one evidence demonstrates that AIs are superior to tamoxifen in reducing recurrence and mortality from estrogen receptor positive postmenopausal breast cancer. 50 Symptom tolerance, however, should also be considered in long-term use of antiestrogen endocrine therapy in view of discontinuation and quality of life.
In addition to our large sample size, a strength of our study is the use of standardized instruments to measure menopausal symptoms, sexual function, quality of life, and endocrine symptoms after breast cancer, providing a comprehensive picture of how chemotherapy impacts menopause-related quality of life. We have recently reported that menopausal symptoms are more frequent and severe in breast cancer survivors compared with the noncancer clinic population, 24 emphasizing the importance of dedicated multidisciplinary services for this population. 23 We chose to examine the impact of chemotherapy on menopausal symptoms, but recognize that chemotherapy will also affect menopause status. In our population, approximately 60% of those who had received chemotherapy reported that that they were premenopausal before chemotherapy compared with approximately 20% of those not receiving chemotherapy. To address the potential impact of chemotherapy-induced menopause on our outcomes, we also compared symptoms and quality of life in those defined as having ''chemotherapy-induced menopause'' with other breast cancer survivors. The only difference observed was that women with chemotherapy-induced menopause had worse pain with intercourse.
Others have found that chemotherapy may adversely affect sleep for up to 1 year after treatment. 51 Although current sleep problems did not differ by chemotherapy status, pastweek severe trouble with poor sleep was more common among breast cancer survivors who had not received chemotherapy. We did not use validated measures of sleep disturbance and so cannot make any conclusive statements on chemotherapy and sleep. As this study examined a large number of outcomes, statistically significant associations may arise exclusively by chance. Our findings with respect to sexual dysfunction among AI users are consistent across instruments and with existing literature, but the unexpected finding regarding sleep, and perhaps even the finding that chemotherapy was associated with dyspareunia, should be interpreted with caution.
A limitation of our study is the use of a clinic rather than community-based sample, likely overrepresenting those with more severe and troublesome menopausal symptoms. This is supported by the observation that measures of treatmentrelated quality of life in our population are worse than those from a normative population of breast cancer patients. This overrepresentation is, however, not likely to be differential by chemotherapy treatment status, and is thus unlikely to conceal a disparity between those treated with and without chemotherapy. A further limitation is that because participants completed instruments while waiting for their appointments, with the assistance of research staff, only about half of participants completed the FACT and SAQ, which were the final instruments in the questionnaire, due to variations in clinic research staff resourcing. Smaller numbers decrease power to detect true differences, biasing our findings toward the null, but it is also possible that the nature of the nonresponders could differ by chemotherapy status, further biasing findings unpredictably. It is reassuring that our findings using the GCS, completed by approximately 90% of participants, were similar to those using the less commonly completed instruments, and that those who did and did not complete instruments were similar in age and menopause status.
We did not have adequate power to examine the contribution of chemotherapy and endocrine therapy independently. The majority (70%) of participants had early breast cancer, and all had completed surgical and chemoradiation treatments. Hence, it is unlikely that current cancer symptoms would have contributed to their symptoms.
CONCLUSIONS
In this large clinic-based population, chemotherapy for breast cancer did not affect vasomotor symptoms or quality of life, but was more commonly associated with severe pain during sexual intercourse that was not apparently attributable to vaginal dryness. Current severe vaginal dryness and pain with intercourse were more common in AI users compared with tamoxifen even when adjusted for age. These findings provide further evidence that sexual function after chemotherapy and in endocrine therapy users should be addressed in clinical management.
